FluoGuide A/S FLUO
OMXSTO · Sweden · Health Technology
SEK 33.90+0.10 (+0.30%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
COPENHAGEN, DK / ACCESS Newswire / August 12, 2026 / FluoGuide A/S (STO:FLUO) will publish its interim report for Q2 2026 on Tuesday, 25 August 2026. Later that day, CEO Morten Albrechtsen and CFO Ole Larsen will present the company's operational ...
COPENHAGEN, DK / ACCESS Newswire / July 1, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO) , a clinical-stage biotech company focused on precision cancer surgery, is pleased to share an update on the 2026 Outlook and ongoing progress. ...
COPENHAGEN, DK / ACCESS Newswire / June 29, 2026 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced positive results from the first part of its ...
KØBENHAVN, DK / ACCESS Newswire / May 13, 2026 / FluoGuide A/S (STO:FLUO) will publish its interim report for Q1 2026 on Wednesday, 27 May 2026. Later that day, CEO Morten Albrechtsen and CFO Ole Larsen will present the company's operational and financial ...
COPENHAGEN, DENMARK / ACCESS Newswire / March 18, 2026 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, announces that the U.S. Food and Drug Administration ...
KØBENHAVN, DK / ACCESS Newswire / November 25, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark, 25 November 2025 - FluoGuide A/S, a biotech company specializing in precision cancer surgery, announces a signed collaboration agreement with ZEISS ...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.